An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)

Roche

Status: Completed

Conditions: Anemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01974271

ML28980

Details and patient eligibility

About

This prospective, multicenter, observational study will evaluate the impact of comorbidities on hemoglobin stability in chronic kidney disease patients on dialysis treated with Mircera (methoxy polyethylene glycol-epoetin beta). Eligible patients will be followed for 6 months of treatment.

Enrollment: 661 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 18 years of age
• Chronic kidney disease patients on hemodialysis or hemodiafiltration for at least 3 months
• Previously treated with an erythropoietin stimulating agent (ESA)
• Patient for whom the investigator decided to initiate treatment with Mircera for medical reasons
• Last hemoglobin level before initiation of Mircera within the range of 10-12 g/dL

Exclusion criteria

• Current participation in a clinical trial on renal anemia

Trial design

661 participants in 1 patient group

Cohort